Amgen Inc. Patent for KRAS G12C Inhibitor Cancer Therapy

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted Amgen Inc. a patent (US12582657B2) for a combination therapy involving a KRAS G12C inhibitor and other agents for treating cancers. The patent covers pharmaceutical compositions and methods of treatment.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12582657B2 to Amgen Inc. This patent covers a combination therapy for cancer treatment that includes a KRAS G12C inhibitor, such as sotorasib or a pharmaceutically acceptable salt thereof, along with one or more additional pharmaceutically active agents. The patent also extends to pharmaceutical compositions containing these agents.

This patent grant represents a new intellectual property right for Amgen concerning a specific cancer treatment modality. While not a regulatory rule imposing obligations on other entities, it signifies a proprietary development in the pharmaceutical sector. Companies involved in oncology research or development, particularly those working with KRAS G12C inhibitors, should be aware of this patent's existence and scope to avoid potential infringement issues.

Source document (simplified)

← USPTO Patent Grants

Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Grant US12582657B2 Kind: B2 Mar 24, 2026

Assignee

Amgen Inc.

Inventors

James Russell Lipford, Jude Robert Canon, Anne Y. Saiki, Karen Louise Rex

Abstract

The present invention provides combination therapy that includes an KRASG12C inhibitor, such as
or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.